NEW YORK, April 30, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Myriad Genetics, Inc. ("Myriad") (NASDAQ:MYGN) between August 13, 2014 and March 12, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Utah. To get more information go to:
http://www.zlk.com/pslra-d/myriad-genetics-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; (ii) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (iii) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (iv) as a result, Myriad’s public statements were materially false and misleading at all relevant times. On March 12, 2018, Myriad Genetics filed an 8-K with the United States Securities and Exchange Commission disclosing the receipt of a subpoena from the Department of Health and Human Services concerning “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.”
If you suffered a loss in Myriad you have until June 19, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat
Japan Earthquake Disrupts Auto and Chip Supply Chains
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth
Same sparkle, different story: how lab-grown diamonds are transforming the market 



